Cardiac sympathetic nerve imaging using 123I-MIBG scintigraphy is a useful tool for evaluating the effectiveness of pharmacological treatments in patients with heart failure.
Do pharmacological treatments improve cardiac sympathetic nerve activity as evaluated by 123I-MIBG scintigraphy in patients with heart failure?
123I-MIBG scintigraphy is a useful imaging modality to evaluate the effectiveness of pharmacological treatments on cardiac sympathetic nerve activity and left ventricular remodeling in patients with heart failure.
The autonomic nervous system plays an important role in the human heart. Activation of the cardiac sympathetic nerve system is a cardinal pathophysiological abnormality associated with the failing human heart. Myocardial imaging using 123I-metaiodobenzylguanidine (MIBG), an analogue of norepinephrine, has been applied to investigate the activity of the predominant neurotransmitter of the sympathetic nervous system. 123I-MIBG uptake in the myocardium is known to be reduced after the onset of heart failure, and improves when heart failure is controlled; therefore, treatments for heart failure may be assessed based on improvements in 123I-MIBG scintigraphic parameters. In this review, we summarized studies that have focused on the use of cardiac sympathetic nerve imaging using 123I-MIBG scintigraphy to evaluate the effectiveness of pharmacological treatments in heart failure patients.
Kasama et al. (Thu,) conducted a review in Heart failure. 123I-MIBG scintigraphy was evaluated. Cardiac sympathetic nerve imaging using 123I-MIBG scintigraphy is a useful tool for evaluating the effectiveness of pharmacological treatments in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: